Accustem Sciences Inc. (ACUT) stock
ACUTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.15+0.00 (0.00%)
Close on Oct 16, 2026Market cap $2.37MP/E –Yield –
Accustem Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Accustem Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $355.70K, up 119.7% year over year. For fiscal 2025 it was $281.01K, up 103.2% from the year before. The highest annual figure on record is $281.01K in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $281.01K | +103.2% |
| FY2024 | Dec 31, 2024 | $138.32K | -1.0% |
| FY2023 | Dec 31, 2023 | $139.66K | -47.7% |
| FY2022 | Dec 31, 2022 | $266.93K | +264.0% |
| FY2021 | Dec 31, 2021 | $73.34K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.71K | -27.4% |
| Q1 FY2026 | Mar 31, 2026 | $119.53K | +321.7% |
| Q4 FY2025 | Dec 31, 2025 | $119.74K | +185.3% |
| Q3 FY2025 | Sep 30, 2025 | $72.72K | +131.5% |
| Q2 FY2025 | Jun 30, 2025 | $60.20K | +44.2% |
| Q1 FY2025 | Mar 31, 2025 | $28.35K | +22.2% |
| Q4 FY2024 | Dec 31, 2024 | $41.97K | -53.1% |
| Q3 FY2024 | Sep 30, 2024 | $31.41K | +57.4% |
| Q2 FY2024 | Jun 30, 2024 | $41.75K | +186.4% |
| Q1 FY2024 | Mar 31, 2024 | $23.20K | +48.7% |
| Q4 FY2023 | Dec 31, 2023 | $89.54K | -32.7% |
| Q3 FY2023 | Sep 30, 2023 | $19.95K | -65.8% |
| Q2 FY2023 | Jun 30, 2023 | $14.58K | -73.2% |
| Q1 FY2023 | Mar 31, 2023 | $15.60K | -26.2% |
| Q4 FY2022 | Dec 31, 2022 | $133.12K | +403.0% |
| Q3 FY2022 | Sep 30, 2022 | $58.27K | +312.5% |
| Q2 FY2022 | Jun 30, 2022 | $54.40K | +80.1% |
| Q1 FY2022 | Mar 31, 2022 | $21.14K | +697.8% |
| Q4 FY2021 | Dec 31, 2021 | $26.47K | – |
| Q3 FY2021 | Sep 30, 2021 | $14.13K | – |
| Q2 FY2021 | Jun 30, 2021 | $30.20K | – |
| Q1 FY2021 | Mar 31, 2021 | $2.65K | – |
See a number that looks wrong?